Blog Masthead (above):
Hero Masthead (below):
Page Nav:
Card Grid:
Media & Content
Teardrop Break:
Background Block with Grid:
Buttons:
Batch 01, below:
CTA block:
Timeline:
-
2002
Catalyst Founded
Board of Directors formed.
-
2002
CPP-109, a GABA analog
In-licensed from Brookhaven National Laboratory for the treatment of cocaine and other addictions (development terminated in 2009)
-
2006
CPRX listed on NASDAQ
-
2009
CPP-115, a GABA aminotransferase (GABA-AT) inactivator
In-licensed from Northwestern University (development terminated 2018)
-
2012
FIRDAPSE® (amifampridine)
Secured North American rights from BioMarin
-
2018
FIRDAPSE
Approved by the U.S. Food and Drug Administration (FDA) for symptoms of Lambert Eaton myasthenic syndrome (LEMS). FIRDAPSE is the first evidence-based product approved by the U.S. FDA for LEMS.
-
2019
FIRDAPSE
Catalyst and BioMarin agree to provide Catalyst with exclusive rights to FIRDAPSE in Japan and potential rights for parts of Asia and Central and South America.
-
2020
FIRDAPSE
Approved in Canada by Health Canada
Sublicensed rights to Kye in Canada
SERB S.A. acquired BioMarin’s overall license for FIRDAPSE and is Catalyst’s global licensor
-
2021
FIRDAPSE
Sublicensed rights in Japan to DyDo Pharma
-
2023
FYCOMPA® (perampanel)
Acquired US rights from Eisai
-
2023
AGAMREE® (vamorolone)
Acquired North American rights from Santhera
Received US FDA approval for DMD -
2024
FIRDAPSE
Received approval in Japan
-
2024
AGAMREE
Launched in the US
Entered license agreement with Kye Pharmaceuticals in Canada -
2025
FIRDAPSE
Commercially available in Japan.
-
2025
AGAMREE
Approved in Canada by Health Canada – first product approved in Canada for DMD
Tabs with Left bar Content border:
Icon / content:
Scrollable ISI:
FW Image block:
1/4 – 3/4 grid layout:
Batch 02, below:
Podcast block:
Fatherhood and Caring in Rare Disease Families
The Courage to Ask for Help in Rare Disease
Bridging the Gap: Rural Healthcare Access in Rare Disease
Overcoming Healthcare Hurdles: Inspiring Stories from Laura Romero and Desiree Taliancich
Empowered by Experience: Rich Daly on Epilepsy and Leadership
Welcome to Catalyst Convos: Empowering Stories and Expert Insights





